Infosys Vs TCS: Who’s leading the IT turnaround race now?

The IT Index saw deep cut in trade on Friday with Infosys shares registered the biggest dent as the street worried about the sustainability of its revenue trajectory. While announcement of TCS Q3 results cheered the market on hopes of a revival in IT deal spends, the expectation that Infosys may have a muted Q4 was decidedly a party pooper.

Comparing the performance of the two major tech belwether in India, DD Mishra, VP Analyst, Gartner highlighted that “TCS and Infosys have both managed to grow in a difficult environment while protecting their margin growth. Although discretionary spending is under pressure and has been below our expectations, but overall, we still anticipate that IT Services spending will grow as per our forecast.”

Here is a quick look at some of the key metrics and how both companies fared on these counts-

Infosys vs TCS: Discretionary Spend

In case of Infosys, the upward revision in the FY25 revenue guidance was primarily on the back of a faster recovery in discretionary spends across the BFSI, retail and consumer verticals. According to the management, the focus is more on cost-takeout deals than on discretionary spends. However, they are positive about the outlook for near-term discretionary spend.

Also ReadWhy is Infosys falling? 4 factors worrying investors are…

TCS meanwhile maintained that there is improvement in discretionary spending and shorter deal cycles. BFSI and telecom are the two sections that they are expecting meaningful improvement in discretionary spend.

Comparing the performances of both Infosys and TCS in Q3, Siddhartha Khemka, Head of Retail Research, Broking and Distribution at Motilal Oswal Financial Services outlined that, “Infosys Q3 headline numbers were strong but revenue was generated primarily by passthrough so it has led to a doubt in the investor’s mind about the sustainability of the revenue trajectory. There are expectation of revenue decline in Q4, about 1% dip QoQ. The market is cautious as a result. Infosys may remain subdued for next quarter.”

Infosys Vs TCS: Deal Pipeline

Infosys management indicated that the company is seeing better client traction in for enterprise AI capabilities, particularlygenerative AI. This as a result helped the tech major clock strong large deal wins and healthydeal pipeline. However,

 » Read More

Related Articles

Trump tariff impact: Pharma stocks surge over 4% on tariff exemption

It’s a party for pharma stocks on Dalal Street. The Nifty Pharma Index is up nearly 4% and Sun Pharma, Gland Pharma and IPCA Labs see gains close to 4% each. Even Lupin and Natco Pharma are rallying smartly. In a major relief, Indian pharmaceutical companies breathed a sigh of relief after US President Donald

Trump tariff impact: Tech stocks plummet, Nifty IT cracks 2.5%

The share price of IT stocks slumped after US President Donald Trump’s administration imposed 26% reciprocal tariffs on Indian imports to the US. The Nifty IT, a basket of Indian tech stocks, fell 2.5% to 35,371.55 levels.  All the constituents of the sectoral index were trading in the red. The share price of Persistent Systems

Trump tariffs send shockwaves across global markets; US futures crash, gold soars to new highs- 10 cues you need to track now

Indian stock markets are set for a turbulent start as global jitters over Trump’s new tariffs weigh on. Early trends from GIFT Nifty point to a sharp drop of over 350 points, signaling a weak opening for Sensex and Nifty 50. Indian stock markets ended on a positive note in the previous trading session, with

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Stay Connected

0FansLike
0FollowersFollow
0SubscribersSubscribe
- Advertisement -

Latest Articles

Trump tariff impact: Pharma stocks surge over 4% on tariff exemption

It’s a party for pharma stocks on Dalal Street. The Nifty Pharma Index is up nearly 4% and Sun Pharma, Gland Pharma and IPCA Labs see gains close to 4% each. Even Lupin and Natco Pharma are rallying smartly. In a major relief, Indian pharmaceutical companies breathed a sigh of relief after US President Donald

Trump tariff impact: Tech stocks plummet, Nifty IT cracks 2.5%

The share price of IT stocks slumped after US President Donald Trump’s administration imposed 26% reciprocal tariffs on Indian imports to the US. The Nifty IT, a basket of Indian tech stocks, fell 2.5% to 35,371.55 levels.  All the constituents of the sectoral index were trading in the red. The share price of Persistent Systems

Trump tariffs send shockwaves across global markets; US futures crash, gold soars to new highs- 10 cues you need to track now

Indian stock markets are set for a turbulent start as global jitters over Trump’s new tariffs weigh on. Early trends from GIFT Nifty point to a sharp drop of over 350 points, signaling a weak opening for Sensex and Nifty 50. Indian stock markets ended on a positive note in the previous trading session, with

‘Pramerica Life targets Rs 3,000-crore GWP in FY26,’ Pankaj Gupta

Pramerica Life Insurance, a joint venture between subsidiaries of Piramal Capital and Housing Finance and US-based Prudential Financial Inc, aims to close FY26 with Rs 3,000 crore in gross written premium. In an interview with Narayanan V, managing director and CEO Pankaj Gupta discusses the products and distribution strategy. Excerpts: Life insurance premiums have been

Tata small cap fund: Targeting growth at reasonable valuations

Tata Small Cap Fund is a growth-oriented scheme in the Small Cap Fund category that has exhibited a noteworthy track record since its inception and has outpaced many of its prominent peers, thereby rewarding investors with superior risk-adjusted returns. Launched in November 2018, Tata Small Cap Fund aims to invest in stocks of companies that are in growth